Register for our free email digests:
Division of diaDexus Inc.
Latest From Shionogi Inc.
This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.
Drugs for hepatitis C and tuberculosis are now being licensed for generic production under the aegis of the Medicines Patent Pool, which says it now has 15 generic manufacturing partners working on more than 100 projects across the hepatitis C, TB and HIV areas.
HIV may be effectively treated and managed with available therapies, but there is still great unmet need for a functional cure and better prevention to stop the epidemic.
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- diaDexus Inc.
- North America
- Parent & Subsidiaries
- diaDexus Inc.
- Diadexus Inc.
- Senior Management
Lori Rafiled, PhD, Chmn. & CEO
Leone Patterson, CFO
Kenneth Fang, MD, CMO
William Hammond, VP, Sales
Jonathan Ruais, VP, Mktg.
- Contact Info
Phone: (650) 246-6400
349 Oyster Pt. Blvd.
South San Francisco, CA 94080-1913
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.